Two Sigma Securities’s Outlook Therapeutics OTLK Stock Holding History

Two Sigma Securities’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6K	Buy	+14,855	New	+$9.21K	﹤0.01%	1469
2025 Q4	–	Sell	-35,664	Closed	-$37.8K	–	1870
2025 Q3	$37.8K	Buy	+35,664	New	+$61.7K	0.01%	1028
2023 Q4	–	Sell	-792	Closed	-$3.5K	–	3436
2023 Q3	$3.5K	Buy	792 +167	+27%	+$3.69K	﹤0.01%	2808
2023 Q2	$21.7K	Buy	+625	New	+$17K	﹤0.01%	2495
2021 Q2	–	Sell	-622	Closed	-$28K	–	1648
2021 Q1	$28K	Buy	+622	New	+$23.8K	﹤0.01%	763
2018 Q4	–	Sell	-115	Closed	-$18K	–	2654
2018 Q3	$18K	Sell	115 -28	-20%	-$3.94K	﹤0.01%	2457
2018 Q2	$19K	Sell	143 -1	-0.7%	-$147	﹤0.01%	2562
2018 Q1	$21K	Sell	144 -103	-42%	-$18.4K	﹤0.01%	2574
2017 Q4	$51K	Buy	247 +173	+234%	+$35.9K	﹤0.01%	1524
2017 Q3	$16K	Buy	+74	New	+$13.5K	﹤0.01%	843

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Two Sigma Securities's OTLK Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 14,855 shares worth $23.6K. The stake represents ﹤0.01% of the portfolio and ranks #1469 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in OTLK as recently as Q3 2025.

Two Sigma Securities first reported a position in OTLK in Q3 2017 and has held it in 10 quarters since. The position peaked at $51K in Q4 2017. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Two Sigma Securities held 14,855 shares of Outlook Therapeutics worth $23.6K as of Q2 2026.
Outlook Therapeutics was a new Two Sigma Securities position in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1469 holding.
Two Sigma Securities first reported a position in Outlook Therapeutics in Q3 2017 and has held it in 10 quarters since.
Two Sigma Securities's Outlook Therapeutics position peaked at $51K in Q4 2017.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.